Arcus Biosciences Inc

NYSE:RCUS  
34.38
+1.87 (+5.75%)
Products

Arcus Biosciences Says Dosed First Subject In ARC-10

Published: 03/16/2021 21:09 GMT
Arcus Biosciences Inc (RCUS) - Arcus Biosciences Inc - Has Dosed First Subject in Arc-10, a Phase 3 Study.
Arcus Biosciences - Dosing of First Subject Triggers Milestone Payments to Wuxi Biologics of $10 Million and Abmuno Therapeutics of $5 Million.
Arcus Biosciences Inc - Will Owe a Subsequent Milestone Payment Upon Initiation of a Phase 3 Trial in a Second Indication.